IntraBio’s Aqneursa Becomes Second Approved NPC Therapy In Four Days

IntraBio and Zevra will go head-to-head in the treatment of Niemann-Pick disease type C, with US FDA approvals of Aqneursa and Miplyffa, respectively, less than a week apart.